Abbott shares trade below $100, while a conservative valuation model puts them near $210 in 2036.
Acquisitions contributed to that expansion. Abbott bought St. The company also acquired Exact Sciences for $21 billion earlier this year, a transaction that is contributing to its 2026 results while adding integration and debt-related risks.
The model’s implication is that Abbott would not need to match its previous growth rate to potentially double its share price over the next decade. A faster 9%-plus earnings-growth rate combined with a somewhat higher valuation could place the shares near $250 in 2036, though that outcome depends on continued operating growth and successful integration of Exact Sciences.